China National Medical Products Administration Approves DOPTELET® (avatrombopag) for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure
- Thursday, April 30, 2020, 7:05
- Finance
- Add a comment
DURHAM, N.C., April 30, 2020 /PRNewswire/ — AkaRx, Inc., a wholly owned subsidiary of Dova Pharmaceuticals, Inc, a Swedish Orphan Biovitrum AB (publ) (Sobi™) company, today announced DOPTELET® (avatrombopag) has been granted approval from the China National Medical Products…
About the Author
adminasapcorp has written 38936 stories on this site.